Compare Amgen, Inc. (AMGN) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while YieldMax TSLA Option Income Strategy ETF trades at $27.28. The key difference: Amgen, Inc. pays a 2.77% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | TSLY | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $388.16 | $48.25 |
52-Week Low | $271.18 | $26.16 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TSLY trades at $27.42, down slightly by 0.04% today, with a bearish technical signal from moving averages and key indicators like ADX. The ETF generates high income through weekly distributions, with recent payouts ranging from $0.28 to $0.52 per share. Support levels are at $26 and $27, while resistance lies near $28 and $29. Recent news highlights consistent dividend announcements from YieldMax, reinforcing its income-focused strategy.
The outlook for TSLY hinges on its ability to sustain high distributions amid market volatility. While the ETF offers attractive yield potential, risks include capped upside from covered call strategies and sensitivity to Tesla's stock performance. Investors should weigh income benefits against volatility and capital erosion risks in a bearish technical environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
